TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00992407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone long acting injectables
Description: Risperidone long acting injectables will be administered intramuscularly (given into the skin) at a flexible dose of 25, 37.5 or 50 milligram (mg) every 2 weeks up to Week 52. A supplementary oral antipsychotic will also be administered for 3-4 weeks after the initial dose of injection.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risperidone tablets
Description: Risperidone tablets will be administered orally as 0.5-10 mg daily up to Week 52.
Study: NCT02924233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab is a humanized immunoglobulin G4 (IgG4) anti-PD-1 monoclonal antibody. Nivolumab will be administered via 60-minute infusion Q2W
Study: NCT01462864

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Structured Lifestyle Education
Description: A 3-4 hours group education delivered in a patient group composed of 4-8 patients and delivered by two healthcare professionals.
Study: NCT03706664

Intervention type: OTHER
Group type: OTHER
Intervention: Machine learning algorithm
Description: Study will develop and test a machine learning algorithm using MR Enterography images labelled by Radiologists.

Intervention type: OTHER
Group type: OTHER
Intervention: Machine learning algorithm
Description: Study will develop and test a machine learning algorithm using MR Enterography images labelled by Radiologists.
Study: NCT03009227

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Colonic resection with D2 lymph node dissection
Description: Appropriate to the tumor location colonic resection is performed with D2 lymph node dissection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonic resection with D3 lymph node dissection
Description: Appropriate to the tumor location colonic resection is performed with D3 lymph node dissection
Study: NCT04457362

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic Arthroscopy using the Arthrex NanoScope
Description: A diagnostic arthroscopy will be performed with the Arthrex NanoScope.~Structures evaluated:~* Radial styloid~* Proximal scaphoid articular cartilage~* Scaphoid fossa~* Radioscaphocapitate (RSC) ligament~* Long radiolunate (LRL) ligament~* Short radiolunate (SRL) ligament~* Scapholunate (SL) ligament~* Proximal lunate articular cartilage~* Lunate fossa~* Triangular fibrocartilage complex (TFCC) The attending performing the diagnostic arthroscopy will make an initial diagnostic assessment based on the presence/location/severity of synovitis, articular cartilage integrity, ligament injury and determine the intended treatment.
Study: NCT03741413

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gain-frame SMS
Description: Emergency recruitment cell phone short messages that emphasizing donating blood can save patients' lives were sent to donors in this group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Loss-frame SMS
Description: Emergency recruitment cell phone short messages emphasizing that donating blood can prevent patients from death were sent to donors in this group.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control SMS
Description: Emergency recruitment cell phone short messages that only mentioning the low Rh-negative blood stockpile were sent to donors in this group.
Study: NCT02939274

Intervention type: DRUG
Group type: OTHER
Intervention: Verteporfin

Intervention type: DEVICE
Group type: OTHER
Intervention: Continuous Low-Irradiance Photodynamic Therapy (CLIPT)
Study: NCT02162758

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole delayed-release capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole
Description: Dexlansoprazole delayed-release capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexlansoprazole Placebo
Description: Dexlansoprazole placebo-matching capsules
Study: NCT01938118

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Obesity Prevention Group

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Injury Prevention Group
Study: NCT03129477

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Telemonitoring in noninvasive ventilation
Description: Compare telemonitoring to conventional monitoring to optimize Ventilation
Study: NCT04965571

Intervention type: GENETIC
Intervention: genetic test
Description: Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA)
Study: NCT01015430

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for RO4917523 ascending doses)
Description: Placebo daily po

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for RO4917523 ascending doses)
Description: Placebo daily po

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for RO4917523 fixed dose)
Description: Placebo daily po

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for RO4917523 fixed dose)
Description: Placebo daily po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523
Description: RO4917523 ascending doses daily po

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4917523
Description: RO4917523 fixed dose daily po
Study: NCT00526578

Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaire taking about 30-40 minutes to complete.
Study: NCT01523899

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xpert MRSA/SA SSTI
Description: Use of Xpert MRSA/SA SSTI assay

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Standard culture
Study: NCT02527096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolutegravir (Tivicay®) - Phase 1
Description: • Phase 1 (8 weeks) : switch of the third agent with dolutegravir(Tivicay®) 50 mg once a day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamivudine (Epivir®) - Phase 2
Description: • Phase 2 (48 weeks): combination with lamivudine (Epivir®) 300 mg once a day + dolutegravir (Tivicay®) 50 mg once a day. Only participants with plasma HIV RNA ≤ 50 cp/mL at Week 8 will continue on phase 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dolutegravir (Tivicay®) - Phase 2
Description: • Phase 2 (48 weeks): combination with lamivudine (Epivir®) 300 mg once a day + dolutegravir (Tivicay®) 50 mg once a day. Only participants with plasma HIV RNA ≤ 50 cp/mL at Week 8 will continue on phase 2.
Study: NCT02492399

Intervention type: PROCEDURE
Group type: OTHER
Intervention: extended myectomy
Description: The scheme of extended septal myectomy: Two parallel incisions were made into the septal bulge and connected to remove the muscle mass. Myectomy was extended to the base of the papillary muscles, when midseptal thickening was present. The papillary muscles were grasped and pushed medially to visualize the abnormal connections between the papillary muscles and the anterior wall of the ventricle. A blade was used to divide the thickened abnormal attachments. A pituitary rongeur may be used to resect a portion of the junction of the papillary and lateral wall. This reduces the diameter of the papillary muscle and allows for posterior displacement of the anterior mitral leaflet. Division of abnormal attachments and thinning of the papillary muscles is critical for the treatment of SAM.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: myectomy by Morrow
Description: A first myotomy is made into the septum just below the base of the right coronary leaflet at a point 2-3 mm to the right of the commissure between the left and right coronary leaflets. A second myotomy is made in the same manner, parallel to the first one and about 1 cm to the right of it. The two vertical myotomies are made and cornnected transversely in the interventricular septum. The muscle bar is then grasped with the angled rongeur and the instrument is pushed firmly toward the apex, peeling the mtusele from its anterior septal attachments. After completion of the resectioni, a rectangular channel about 1 X 1.5 cm is palpable from the valve ring toward the apex for a dis- tance of about 4 cm.
Study: NCT06141096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB07133
Description: Evaluate the effectiveness and safety of different doses of MB07133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB07133
Description: Evaluate the effectiveness and safety of different doses of MB07133

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MB07133
Description: Evaluate the effectiveness and safety of different doses of MB07133
Study: NCT03714295

Intervention type: OTHER
Intervention: Use of interdental brushes
Description: No intervention they just use interdental brushes as it should be done routinely

Intervention type: OTHER
Intervention: Use of interdental brushes
Description: No intervention they just use interdental brushes as it should be done routinely
Study: NCT00337571

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Tablets, Oral, once daily, 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Tablets, Oral, once daily, 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Tablets, Oral, once daily, 8 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, once daily, 8 weeks
Study: NCT02336737

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SiennaXP
Description: Sub-cutaneous injection of SiennaXP magnetic marker, followed by lymph node localization using the SentiMag handheld magnetic probe

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technetium Tc99m Sulfur Colloid
Description: Injection of a single dose of radioisotope (Technetium Tc99m Sulfur Colloid)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isosulfan blue dye
Description: Injection of a single dose of isosulfan blue dye
Study: NCT01083875

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amlexanox
Description: 0.5% amlexanox oral rinse; use 5 ml every 2-3 hours during the awake hours of each day (a minimum of 6 times each day). The liquid was be swirled around the mouth then to be swallowed. Repeated daily until completion of radiation therapy: approximately 7-8 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle rinse
Description: use 5 ml of the vehicle rinse every 2-3 hours during the awake hours of each day (a minimum of 6 times each day). The liquid is be swirled around the mouth then swallowed.
Study: NCT01621464

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pacemaker with Closed Loop Stimulation (CLS sensor)
Description: Crossover: 1 year at control group and 1 year at CLS group (randomized which group goes first)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Pacemaker with Closed Loop Stimulation (CLS sensor)
Description: Crossover: 1 year at control group and 1 year at CLS group (randomized which group goes first)
Study: NCT03383744

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin A supplementation
Description: Each child received one capsule of 200,000 IU of vitamin A

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin A supplementation
Description: Each child received one capsule of 200,000 IU of vitamin A
Study: NCT04267666

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: incentive spirometer
Description: Patient had to produce a high inspiratory pressure. The ball serves as visible feedback of the inspiratory flow and indicates the obtained flow on a calibrated scale on the transparent cylinder of the spirometer. If the patient flows greater than 300 milliliters per second, the float ball in first chamber will rise. As patient flow increases to 600 milliliters per second the second ball float will rise. If the patient flow exceeds 900 milliliters per second all three will be suspended. Patient should encourage holding the balls up for a few seconds

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle trainer device
Description: The threshold trainer is a small plastic handheld device supplied by respironics. It includes a mouthpiece and a calibrated spring loaded valve. The valve controls a constant inspiratory pressure training load and the patient must generate the inspiratory pressure in order for the inspiratory valve to be opened and allow inhalation of air.
Study: NCT02888171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferric citrate
Description: Participants randomized to the ferric citrate arm will take 2 grams of ferric citrate three times a day with meals.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferrous sulfate
Description: Participants randomized to the ferrous sulfate arm will take 325 mg of ferrous sulfate three times a day.
Study: NCT01729130

Intervention type: PROCEDURE
Intervention: Adipose tissue biopsy
Description: Adipose tissue biopsy is done at time of transplant surgery. There is a second needle biopsy done between 3-12 months post transplant surgery.

Intervention type: PROCEDURE
Intervention: Adipose tissue biopsy
Description: Adipose tissue biopsy is done at time of transplant surgery. There is a second needle biopsy done between 3-12 months post transplant surgery.

Intervention type: PROCEDURE
Intervention: Adipose tissue biopsy
Description: Adipose tissue biopsy is done at time of transplant surgery. There is a second needle biopsy done between 3-12 months post transplant surgery.
Study: NCT05647486

Intervention type: OTHER
Intervention: 30-day postoperative outcome
Description: The 30-day postoperative outcome after elective EVAR and the role of possible predictors among patients' baseline characteristics were assessed
Study: NCT02177084

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTNS
Study: NCT02141100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6-thioguanine
Description: All eligible patients will be supplemented with 6-thioguanine in addition to the standard therapy with 6-mercaptopurine and methotrexate.~In case of significant myelo-/hepatotoxicity all therapy will be paused. If patients develop VOD they will be excluded from further 6TG therapy.
Study: NCT00750659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib
Description: Nilotinib 400 mg po/BID until transplant. Nilotinib 200-400 mg po/BID post transplant in escalated doses.
Study: NCT01945138

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed Loop Insulin
Description: The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).
Study: NCT03879200

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group antenatal care
Description: Care will be provided in group sessions in dialogue sensitive to language and cultural issues. Group numbers will be around 8; the woman with partner or other companion welcome. The content of the sessions will be designed in collaboration with midwives and Somali born women, following the present parental education and findings from the focus groups. The sessions will be held at the antenatal clinic led by one or two midwife, assisted by the trained female Somali interpreter.
Study: NCT02270788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crenolanib
Description: Day 1 of Course 1: once followed by pharmacokinetic analysis. Days 2-28 of cycle 1: 3 times per day Crenolanib dose will not be adjusted unless the participant experiences side effects.~All subsequent courses: 3 times per day on Days 1-28. At least 50% of participants in each dose level must be ≤ 18 years old.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Days 8-28 of course 1: given orally once each day.~All subsequent courses: given orally on days 1-28 once per day~This is a dose-finding study for the use of sorafenib in combination with crenolanib. Different doses will be given to several participants, with the first participants receiving a lower dose than typically used in children as a single agent. If the drug does not cause serious side effects, it will be given to other study participants at a higher dose. If side effects occur, the dose will be lowered.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate, hydrocortisone and cytarabine with leucovorin
Description: Triple IT therapy includes methotrexate, hydrocortisone and cytarabine with leucovorin rescue given on day 8. All participants will receive one IT chemotherapy on Day 8 of the first cycle. If they do not have leukemia cells in their spinal fluid, they will receive only one IT chemotherapy per cycle. If leukemia cells are present in their spinal fluid, they will receive IT chemotherapy weekly during the course. Triple IT therapy will be repeated on Day 1 of Cycle 2 and with each subsequent cycle in all participants.
Study: NCT04457362

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Diagnostic Arthroscopy using standard arthroscopic instruments
Description: A diagnostic arthroscopy will be performed with the standard arthroscopic instruments.~Structures evaluated:~* Radial styloid~* Proximal scaphoid articular cartilage~* Scaphoid fossa~* Radioscaphocapitate (RSC) ligament~* Long radiolunate (LRL) ligament~* Short radiolunate (SRL) ligament~* Scapholunate (SL) ligament~* Proximal lunate articular cartilage~* Lunate fossa~* Triangular fibrocartilage complex (TFCC) The attending performing the diagnostic arthroscopy will make the final diagnostic assessment based on the presence/location/severity of synovitis, articular cartilage integrity, and ligament injury and determine the final treatment.
Study: NCT03938363

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill
Description: Walk on the Biodex Gait Trainer (TM) 3 Treadmill for registration of gait parameters Gait parameters will be evaluated 5 weeks after Botulinum Toxin injection for the two experimental groups and 5 weeks after the first evaluation for the control groups

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill
Description: Walk on the Biodex Gait Trainer (TM) 3 Treadmill for registration of gait parameters Gait parameters will be evaluated 5 weeks after Botulinum Toxin injection for the two experimental groups and 5 weeks after the first evaluation for the control groups

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treadmill
Description: Walk on the Biodex Gait Trainer (TM) 3 Treadmill for registration of gait parameters Gait parameters will be evaluated 5 weeks after Botulinum Toxin injection for the two experimental groups and 5 weeks after the first evaluation for the control groups

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Treadmill
Description: Walk on the Biodex Gait Trainer (TM) 3 Treadmill for registration of gait parameters Gait parameters will be evaluated 5 weeks after Botulinum Toxin injection for the two experimental groups and 5 weeks after the first evaluation for the control groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin injection
Description: injection of Botulinum Toxin in the two groups of CD and BS

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum Toxin injection
Description: injection of Botulinum Toxin in the two groups of CD and BS

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Severity scale of the disease
Description: JRS for BS TWSTRS for CD
Study: NCT04393532

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Su2ura Approximation Device
Description: the use of the study device during a laparoscopic surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic hernia repair surgery
Description: repairing primary umbilical hernia in a laparoscopic procedure using the study device.
Study: NCT01780883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melatonin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melatonin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melatonin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets of Circadin®

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets of Circadin®

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets of Circadin®
Study: NCT00937937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinaciclib
Description: Given IV
Study: NCT02485834

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FDG-PET

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU
Description: 200 mg/m\^2/day IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: capecitabine
Description: oral 800 mg/m\^2 BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: 30 mg/m\^2 IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 50 mg/m\^2 IV

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 3D-CRT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Study: NCT04080128

Intervention type: DEVICE
Group type: OTHER
Intervention: Contact lenses
Description: Depending on the results of the BLINK Study either a single vision spherical contact lens or a multifocal contact lens.
Study: NCT03170141

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antigen-specific IgT cells
Description: Tumor antigen-specific IgT cells are infused intravenously . Drug: cyclophosphamide 250 mg/m\^2 d1-3; Drug: Fludarabine 25mg/m\^2 d1-3
Study: NCT03938363

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Severity scale of the disease
Description: JRS for BS TWSTRS for CD
Study: NCT05003284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: acupressure wristband
Description: acupressure after surgery

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: placebo wristband
Description: acupressure after surgery
Study: NCT03940950

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Adipose-Derived SVF (Stromal Vascular Fraction)
Description: 60 ml of fat is collected from subjects abdominal wall and SVF is removed from the fat. The SVF is injected into the knee through a needle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline control that contains no active ingredient